

William E Klunk

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/244878/publications.pdf>

Version: 2024-02-01

230
papers

47,490
citations

8181

76
h-index

1980

206
g-index

248
all docs

248
docs citations

248
times ranked

30149
citing authors

#	ARTICLE	IF	CITATIONS
1	The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging and Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2011, 7, 263-269.	0.8	12,681
2	Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. <i>Annals of Neurology</i> , 2004, 55, 306-319.	5.3	3,777
3	Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease. <i>New England Journal of Medicine</i> , 2012, 367, 795-804.	27.0	3,005
4	Molecular, Structural, and Functional Characterization of Alzheimer's Disease: Evidence for a Relationship between Default Activity, Amyloid, and Memory. <i>Journal of Neuroscience</i> , 2005, 25, 7709-7717.	3.6	1,839
5	Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid A β ₄₂ in humans. <i>Annals of Neurology</i> , 2006, 59, 512-519.	5.3	1,190
6	Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 1924.	7.4	1,166
7	Frequent Amyloid Deposition Without Significant Cognitive Impairment Among the Elderly. <i>Archives of Neurology</i> , 2008, 65, 1509.	4.5	923
8	Synthesis and Evaluation of ¹¹ C-Labeled 6-Substituted 2-Arylbenzothiazoles as Amyloid Imaging Agents. <i>Journal of Medicinal Chemistry</i> , 2003, 46, 2740-2754.	6.4	921
9	Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease. <i>Brain</i> , 2008, 131, 1630-1645.	7.6	837
10	¹¹ C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnesic mild cognitive impairment. <i>Brain</i> , 2008, 131, 665-680.	7.6	819
11	β -amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. <i>Brain</i> , 2007, 130, 2837-2844.	7.6	739
12	Longitudinal assessment of A β and cognition in aging and Alzheimer disease. <i>Annals of Neurology</i> , 2011, 69, 181-192.	5.3	730
13	Fibrillar amyloid- β burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 6820-6825.	7.1	700
14	¹¹ C-PiB PET assessment of change in fibrillar amyloid- β load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. <i>Lancet Neurology</i> , 2010, 9, 363-372.	10.2	674
15	Kinetic Modeling of Amyloid Binding in Humans using PET Imaging and Pittsburgh Compound-B. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2005, 25, 1528-1547.	4.3	622
16	The Centiloid Project: Standardizing quantitative amyloid plaque estimation by PET. <i>Alzheimer's and Dementia</i> , 2015, 11, 1.	0.8	603
17	Validating novel tau positron emission tomography tracer [¹⁸ F]AV-451 (T807) on postmortem brain tissue. <i>Annals of Neurology</i> , 2015, 78, 787-800.	5.3	535
18	Brain Imaging in Alzheimer Disease. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2012, 2, a006213-a006213.	6.2	502

#	ARTICLE	IF	CITATIONS
19	Prevalence of Amyloid PET Positivity in Dementia Syndromes. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 1939.	7.4	501
20	Imaging of amyloid burden and distribution in cerebral amyloid angiopathy. <i>Annals of Neurology</i> , 2007, 62, 229-234.	5.3	465
21	Uncharged thioflavin-T derivatives bind to amyloid-beta protein with high affinity and readily enter the brain. <i>Life Sciences</i> , 2001, 69, 1471-1484.	4.3	408
22	Simplified quantification of Pittsburgh Compound B amyloid imaging PET studies: a comparative analysis. <i>Journal of Nuclear Medicine</i> , 2005, 46, 1959-72.	5.0	398
23	Imaging A β Plaques in Living Transgenic Mice with Multiphoton Microscopy and Methoxy-XO4, a Systemically Administered Congo Red Derivative. <i>Journal of Neuropathology and Experimental Neurology</i> , 2002, 61, 797-805.	1.7	366
24	Amyloid Deposition Begins in the Striatum of Presenilin-1 Mutation Carriers from Two Unrelated Pedigrees. <i>Journal of Neuroscience</i> , 2007, 27, 6174-6184.	3.6	358
25	Binding of the Positron Emission Tomography Tracer Pittsburgh Compound-B Reflects the Amount of Amyloid- β in Alzheimer's Disease Brain But Not in Transgenic Mouse Brain. <i>Journal of Neuroscience</i> , 2005, 25, 10598-10606.	3.6	357
26	Mechanism of Amyloid Removal in Patients With Alzheimer Disease Treated With Gantenerumab. <i>Archives of Neurology</i> , 2012, 69, 198.	4.5	349
27	A lipophilic thioflavin-T derivative for positron emission tomography (PET) imaging of amyloid in brain. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2002, 12, 295-298.	2.2	343
28	Molecular Imaging With Pittsburgh Compound B Confirmed at Autopsy. <i>Archives of Neurology</i> , 2007, 64, 431.	4.5	326
29	Amyloid imaging in mild cognitive impairment subtypes. <i>Annals of Neurology</i> , 2009, 65, 557-568.	5.3	309
30	Neuroimaging markers for the prediction and early diagnosis of Alzheimer's disease dementia. <i>Trends in Neurosciences</i> , 2011, 34, 430-442.	8.6	309
31	In Vivo Optical Imaging of Amyloid Aggregates in Brain: Design of Fluorescent Markers. <i>Angewandte Chemie - International Edition</i> , 2005, 44, 5452-5456.	13.8	303
32	Quantifying Amyloid β -Peptide (A β) Aggregation Using the Congo Red-A β (CR β -A β) Spectrophotometric Assay. <i>Analytical Biochemistry</i> , 1999, 266, 66-76.	2.4	283
33	The Binding of 2-(4-Methylaminophenyl)Benzothiazole to Postmortem Brain Homogenates Is Dominated by the Amyloid Component. <i>Journal of Neuroscience</i> , 2003, 23, 2086-2092.	3.6	269
34	Beta Amyloid in Alzheimer's Disease: Increased Deposition in Brain Is Reflected in Reduced Concentration in Cerebrospinal Fluid. <i>Biological Psychiatry</i> , 2009, 65, 927-934.	1.3	256
35	X-34, A Fluorescent Derivative of Congo Red: A Novel Histochemical Stain for Alzheimer's Disease Pathology. <i>Journal of Histochemistry and Cytochemistry</i> , 2000, 48, 1223-1232.	2.5	253
36	Four-dimensional multiphoton imaging of brain entry, amyloid binding, and clearance of an amyloid- β ligand in transgenic mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 12462-12467.	7.1	253

#	ARTICLE	IF	CITATIONS
37	Basal Cerebral Metabolism May Modulate the Cognitive Effects of A β in Mild Cognitive Impairment: An Example of Brain Reserve. <i>Journal of Neuroscience</i> , 2009, 29, 14770-14778.	3.6	217
38	Imaging of amyloid plaques and cerebral glucose metabolism in semantic dementia and Alzheimer's disease. <i>NeuroImage</i> , 2008, 39, 619-633.	4.2	201
39	Absence of Pittsburgh Compound B Detection of Cerebral Amyloid β in a Patient With Clinical, Cognitive, and Cerebrospinal Fluid Markers of Alzheimer Disease. <i>Archives of Neurology</i> , 2009, 66, 1557-62.	4.5	188
40	Developing an international network for Alzheimer's research: the Dominantly Inherited Alzheimer Network. <i>Clinical Investigation</i> , 2012, 2, 975-984.	0.0	180
41	Pathological correlations of β -amyloid imaging in non-Alzheimer tauopathies. <i>Annals of Neurology</i> , 2017, 81, 117-128.	5.3	174
42	Development of small molecule probes for the Beta-amyloid protein of Alzheimer's Disease. <i>Neurobiology of Aging</i> , 1994, 15, 691-698.	3.1	171
43	Alterations of cerebral metabolism in probable Alzheimer's disease: A preliminary study. <i>Neurobiology of Aging</i> , 1994, 15, 117-132.	3.1	171
44	Amyloid burden and neural function in people at risk for Alzheimer's Disease. <i>Neurobiology of Aging</i> , 2014, 35, 576-584.	3.1	166
45	Early detection of Alzheimer's disease using PiB and FDG PET. <i>Neurobiology of Disease</i> , 2014, 72, 117-122.	4.4	164
46	Anti-A β antibody treatment promotes the rapid recovery of amyloid-associated neuritic dystrophy in PDAPP transgenic mice. <i>Journal of Clinical Investigation</i> , 2005, 115, 428-433.	8.2	161
47	Pulse wave velocity is associated with β -amyloid deposition in the brains of very elderly adults. <i>Neurology</i> , 2013, 81, 1711-1718.	1.1	156
48	Development of Positron Emission Tomography β -Amyloid Plaque Imaging Agents. <i>Seminars in Nuclear Medicine</i> , 2012, 42, 423-432.	4.6	155
49	Multisite study of the relationships between antemortem [^{11}C]PiB-PET Centiloid values and postmortem measures of Alzheimer's disease neuropathology. <i>Alzheimer's and Dementia</i> , 2019, 15, 205-216.	0.8	155
50	Arterial Stiffness and β -Amyloid Progression in Nondemented Elderly Adults. <i>JAMA Neurology</i> , 2014, 71, 562.	9.0	152
51	Visualization of fibrillar amyloid deposits in living, transgenic <i>Caenorhabditis elegans</i> animals using the sensitive amyloid dye, X-34. <i>Neurobiology of Aging</i> , 2001, 22, 217-226.	3.1	147
52	Amyloid- β ^{11}C -PiB-PET imaging results from 2 randomized bapineuzumab phase 3 AD trials. <i>Neurology</i> , 2015, 85, 692-700.	1.1	136
53	Association of Cerebral Amyloid- β Aggregation With Cognitive Functioning in Persons Without Dementia. <i>JAMA Psychiatry</i> , 2018, 75, 84.	11.0	133
54	Amyloid Imaging With Carbon 11-Labeled Pittsburgh Compound B for Traumatic Brain Injury. <i>JAMA Neurology</i> , 2014, 71, 23.	9.0	132

#	ARTICLE	IF	CITATIONS
55	Amyloid imaging as a biomarker for cerebral β -amyloidosis and risk prediction for Alzheimer dementia. <i>Neurobiology of Aging</i> , 2011, 32, S20-S36.	3.1	120
56	Imaging Alzheimer Pathology in Late-Life Depression With PET and Pittsburgh Compound-B. <i>Alzheimer Disease and Associated Disorders</i> , 2008, 22, 261-268.	1.3	119
57	PK11195 labels activated microglia in Alzheimer's disease and in vivo in a mouse model using PET. <i>Neurobiology of Aging</i> , 2009, 30, 1217-1226.	3.1	118
58	Evaluation of voxel-based methods for the statistical analysis of PIB PET amyloid imaging studies in Alzheimer's disease. <i>NeuroImage</i> , 2006, 33, 94-102.	4.2	116
59	Imaging brain amyloid in nondemented young adults with Down syndrome using Pittsburgh compound B. <i>Alzheimer's and Dementia</i> , 2012, 8, 496-501.	0.8	116
60	Impact of amyloid imaging on drug development in Alzheimer's disease. <i>Nuclear Medicine and Biology</i> , 2007, 34, 809-822.	0.6	115
61	Subjective Cognitive Complaints, Personality and Brain Amyloid-beta in Cognitively Normal Older Adults. <i>American Journal of Geriatric Psychiatry</i> , 2015, 23, 985-993.	1.2	112
62	Consideration of Optimal Time Window for Pittsburgh Compound B PET Summed Uptake Measurements. <i>Journal of Nuclear Medicine</i> , 2009, 50, 348-355.	5.0	108
63	The 5-HTTPR Polymorphism Confers Liability to a Combined Phenotype of Psychotic and Aggressive Behavior in Alzheimer Disease. <i>International Psychogeriatrics</i> , 2001, 13, 401-409.	1.0	103
64	Progression of Cerebral Amyloid Load Is Associated with the Apolipoprotein E ϵ 4 Genotype in Alzheimer's Disease. <i>Biological Psychiatry</i> , 2010, 68, 879-884.	1.3	103
65	In Vivo Fibrillar β -Amyloid Detected Using [11C]PiB Positron Emission Tomography and Neuropathologic Assessment in Older Adults. <i>Archives of Neurology</i> , 2011, 68, 232-40.	4.5	102
66	Correspondence between in vivo 11C-PiB-PET amyloid imaging and postmortem, region-matched assessment of plaques. <i>Acta Neuropathologica</i> , 2012, 124, 823-831.	7.7	98
67	Standardization of amyloid quantitation with florbetapir standardized uptake value ratios to the Centiloid scale. <i>Alzheimer's and Dementia</i> , 2018, 14, 1565-1571.	0.8	98
68	Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum. <i>JAMA Neurology</i> , 2022, 79, 228.	9.0	97
69	Using a reference tissue model with spatial constraint to quantify [11C]Pittsburgh compound B PET for early diagnosis of Alzheimer's disease. <i>NeuroImage</i> , 2007, 36, 298-312.	4.2	96
70	Longitudinal assessment of neuroimaging and clinical markers in autosomal dominant Alzheimer's disease: a prospective cohort study. <i>Lancet Neurology</i> , The, 2015, 14, 804-813.	10.2	91
71	Small-molecule PET Tracers for Imaging Proteinopathies. <i>Seminars in Nuclear Medicine</i> , 2017, 47, 553-575.	4.6	91
72	Clinical severity of Alzheimer's disease is associated with PIB uptake in PET. <i>Neurobiology of Aging</i> , 2009, 30, 1902-1909.	3.1	89

#	ARTICLE	IF	CITATIONS
73	In vivo assessment of amyloid- β deposition in nondemented very elderly subjects. <i>Annals of Neurology</i> , 2013, 73, 751-761.	5.3	89
74	Cognitive functioning in relation to brain amyloid- β in healthy adults with Down syndrome. <i>Brain</i> , 2014, 137, 2556-2563.	7.6	87
75	The future of amyloid-beta imaging: a tale of radionuclides and tracer proliferation. <i>Current Opinion in Neurology</i> , 2008, 21, 683-687.	3.6	85
76	Comparison of Pittsburgh compound B and florbetapir in cross-sectional and longitudinal studies. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2019, 11, 180-190.	2.4	84
77	Fluid and PET biomarkers for amyloid pathology in Alzheimer's disease. <i>Molecular and Cellular Neurosciences</i> , 2019, 97, 3-17.	2.2	82
78	Amyloid- β Imaging in Older Adults Presenting to a Memory Clinic with Subjective Cognitive Decline: A Pilot Study. <i>Journal of Alzheimer's Disease</i> , 2015, 48, S151-S159.	2.6	80
79	Distinct cytokine profiles in human brains resilient to Alzheimer's pathology. <i>Neurobiology of Disease</i> , 2019, 121, 327-337.	4.4	79
80	Using Pittsburgh Compound B for In Vivo PET Imaging of Fibrillar Amyloid-Beta. <i>Advances in Pharmacology</i> , 2012, 64, 27-81.	2.0	78
81	Early AD pathology in a [C-11]PiB-negative case: a PiB-amyloid imaging, biochemical, and immunohistochemical study. <i>Acta Neuropathologica</i> , 2012, 123, 433-447.	7.7	78
82	Classification of amyloid-positivity in controls: Comparison of visual read and quantitative approaches. <i>NeuroImage</i> , 2013, 71, 207-215.	4.2	77
83	Cognitive trajectories associated with β -amyloid deposition in the oldest-old without dementia. <i>Neurology</i> , 2013, 80, 1378-1384.	1.1	77
84	Analysis of magnetic resonance spectra by mole percent: Comparison to absolute units. <i>Neurobiology of Aging</i> , 1994, 15, 133-140.	3.1	76
85	Post-mortem histopathology underlying β -amyloid PET imaging following flutemetamol F 18 injection. <i>Acta Neuropathologica Communications</i> , 2016, 4, 130.	5.2	76
86	Utilizing the Centiloid scale in cross-sectional and longitudinal PiB PET studies. <i>NeuroImage: Clinical</i> , 2018, 19, 406-416.	2.7	76
87	Characterizing regional correlation, laterality and symmetry of amyloid deposition in mild cognitive impairment and Alzheimer's disease with Pittsburgh Compound B. <i>Journal of Neuroscience Methods</i> , 2008, 172, 277-282.	2.5	75
88	Imaging the pathology of Alzheimer's disease: amyloid-imaging with positron emission tomography. <i>Neuroimaging Clinics of North America</i> , 2003, 13, 781-789.	1.0	74
89	Incidental Cerebral Microbleeds and Cerebral Blood Flow in Elderly Individuals. <i>JAMA Neurology</i> , 2015, 72, 1021.	9.0	71
90	Imaging Technology for Neurodegenerative Diseases. <i>Archives of Neurology</i> , 2005, 62, 196.	4.5	69

#	ARTICLE	IF	CITATIONS
91	[¹⁸ F]AV-451 positron emission tomography retention in choroid plexus: More than a target binding. <i>Annals of Neurology</i> , 2016, 80, 307-308.	5.3	66
92	Association of Brain Amyloid- β^2 With Slow Gait in Elderly Individuals Without Dementia. <i>JAMA Neurology</i> , 2017, 74, 82.	9.0	66
93	The effects of normal aging on amyloid- β^2 deposition in nondemented adults with Down syndrome as imaged by carbon 11-labeled Pittsburgh compound B. <i>Alzheimer's and Dementia</i> , 2016, 12, 380-390.	0.8	65
94	Markers of cholesterol transport are associated with amyloid deposition in the brain. <i>Neurobiology of Aging</i> , 2014, 35, 802-807.	3.1	62
95	Relative ¹¹ C-PiB Delivery as a Proxy of Relative CBF: Quantitative Evaluation Using Single-Session ¹⁵ O-Water and ¹¹ C-PiB PET. <i>Journal of Nuclear Medicine</i> , 2015, 56, 1199-1205.	5.0	62
96	Psychosis in Alzheimer disease: postmortem magnetic resonance spectroscopy evidence of excess neuronal and membrane phospholipid pathology. <i>Neurobiology of Aging</i> , 2002, 23, 547-553.	3.1	60
97	Longitudinal Cerebral Blood Flow and Amyloid Deposition: An Emerging Pattern?. <i>Journal of Nuclear Medicine</i> , 2008, 49, 1465-1471.	5.0	59
98	Cognitive decline and brain amyloid- β^2 accumulation across 3 years in adults with Down syndrome. <i>Neurobiology of Aging</i> , 2017, 58, 68-76.	3.1	59
99	Prevalence of the apolipoprotein E ϵ^4 allele in amyloid β^2 positive subjects across the spectrum of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2018, 14, 913-924.	0.8	58
100	Psychotic Symptoms in Alzheimer's Disease Are Not Associated With More Severe Neuropathologic Features. <i>International Psychogeriatrics</i> , 2000, 12, 547-558.	1.0	56
101	Update on amyloid imaging: From healthy aging to Alzheimer's disease. <i>Current Neurology and Neuroscience Reports</i> , 2009, 9, 345-352.	4.2	55
102	β^2 Imaging: feasible, pertinent, and vital to progress in Alzheimer's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 39, 209-219.	6.4	55
103	Two-year follow-up of amyloid deposition in patients with Alzheimer's disease. <i>Brain</i> , 2006, 129, 2805-2807.	7.6	54
104	Positron emission tomography radioligands for <i>in vivo</i> imaging of A β^2 plaques. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2013, 56, 89-95.	1.0	53
105	³⁴ S Labeling of Abnormal Protein Aggregates During the Progression of Alzheimer's Disease. <i>Methods in Enzymology</i> , 2006, 412, 123-144.	1.0	52
106	Longitudinal changes in amyloid positron emission tomography and volumetric magnetic resonance imaging in the nondemented Down syndrome population. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2017, 9, 1-9.	2.4	49
107	Comparison of qualitative and quantitative imaging characteristics of [¹¹ C]PiB and [¹⁸ F]flutemetamol in normal control and Alzheimer's subjects. <i>NeuroImage: Clinical</i> , 2015, 9, 592-598.	2.7	48
108	Inter-rater reliability of manual and automated region-of-interest delineation for PiB PET. <i>NeuroImage</i> , 2011, 55, 933-941.	4.2	47

#	ARTICLE	IF	CITATIONS
109	Genome-wide association study of brain amyloid deposition as measured by Pittsburgh Compound-B (PiB)-PET imaging. <i>Molecular Psychiatry</i> , 2021, 26, 309-321.	7.9	47
110	Amyloid imaging in dementias with atypical presentation. , 2012, 8, 389-398.		46
111	Hyperphosphorylated Tau is Elevated in Alzheimer's Disease with Psychosis. <i>Journal of Alzheimer's Disease</i> , 2014, 39, 759-773.	2.6	46
112	Amyloid, neurodegeneration, and small vessel disease as predictors of dementia in the oldest-old. <i>Neurology</i> , 2014, 83, 1804-1811.	1.1	46
113	Quantitative Amyloid Imaging in Autosomal Dominant Alzheimer's Disease: Results from the DIAN Study Group. <i>PLoS ONE</i> , 2016, 11, e0152082.	2.5	45
114	β -Amyloid 42/40 ratio and kalirin expression in Alzheimer disease with psychosis. <i>Neurobiology of Aging</i> , 2012, 33, 2807-2816.	3.1	40
115	Lack of association between 11C-PiB and longitudinal brain atrophy in non-demented older individuals. <i>Neurobiology of Aging</i> , 2011, 32, 2123-2130.	3.1	39
116	More evidence for association of a rare TREM2 mutation (R47H) with Alzheimer's disease risk. <i>Neurobiology of Aging</i> , 2015, 36, 2443.e21-2443.e26.	3.1	39
117	Direct Comparison of the Tau PET Tracers ^{18}F -Flortaucipir and ^{18}F -MK-6240 in Human Subjects. <i>Journal of Nuclear Medicine</i> , 2022, 63, 108-116.	5.0	39
118	Improving brain age prediction models: incorporation of amyloid status in Alzheimer's disease. <i>Neurobiology of Aging</i> , 2020, 87, 44-48.	3.1	38
119	Disclosure of amyloid imaging results to research participants: Has the time come?. <i>Alzheimer's and Dementia</i> , 2013, 9, 741.	0.8	37
120	Amyloid deposition and brain structure as long-term predictors of MCI, dementia, and mortality. <i>Neurology</i> , 2018, 90, e1920-e1928.	1.1	36
121	Development of a Standardized Approach to Disclosing Amyloid Imaging Research Results in Mild Cognitive Impairment. <i>Journal of Alzheimer's Disease</i> , 2016, 52, 17-24.	2.6	35
122	Predicting Symptom Onset in Sporadic Alzheimer Disease With Amyloid PET. <i>Neurology</i> , 2021, 97, e1823-e1834.	1.1	35
123	Neuropathological correlates of amyloid PET imaging in Down syndrome. <i>Developmental Neurobiology</i> , 2019, 79, 750-766.	3.0	34
124	Post-mortem analyses of PiB and flutemetamol in diffuse and cored amyloid- β plaques in Alzheimer's disease. <i>Acta Neuropathologica</i> , 2020, 140, 463-476.	7.7	34
125	Variant-dependent heterogeneity in amyloid β burden in autosomal dominant Alzheimer's disease: cross-sectional and longitudinal analyses of an observational study. <i>Lancet Neurology</i> , The, 2022, 21, 140-152.	10.2	34
126	Amyloid β Deposition and Suspected Non-Alzheimer Pathophysiology and Cognitive Decline Patterns for 12 Years in Oldest Old Participants Without Dementia. <i>JAMA Neurology</i> , 2018, 75, 88.	9.0	33

#	ARTICLE	IF	CITATIONS
127	Targeting Prion Amyloid Deposits In Vivo. Journal of Neuropathology and Experimental Neurology, 2004, 63, 775-784.	1.7	32
128	Cognitive aging in persons with minimal amyloid- β^2 and white matter hyperintensities. Neuropsychologia, 2013, 51, 2202-2209.	1.6	31
129	Tenascin-C Is Associated with Cored Amyloid- β^2 Plaques in Alzheimer Disease and Pathology Burdened Cognitively Normal Elderly. Journal of Neuropathology and Experimental Neurology, 2016, 75, 868-876.	1.7	31
130	Sleep moderates the relationship between amyloid beta and memory recall. Neurobiology of Aging, 2018, 71, 142-148.	3.1	31
131	A multi-scanner neuroimaging data harmonization using RAVEL and ComBat. NeuroImage, 2021, 245, 118703.	4.2	31
132	L-Phosphoserine, a Metabolite Elevated in Alzheimer's Disease, Interacts with Specific L-Glutamate Receptor Subtypes. Journal of Neurochemistry, 1991, 56, 1997-2003.	3.9	30
133	Radiosynthesis, <i>In Vitro</i> and <i>In Vivo</i> Evaluation of [¹⁸ F]CBD-2115 as a First-in-Class Radiotracer for Imaging 4R-Tauopathies. ACS Chemical Neuroscience, 2021, 12, 596-602.	3.5	29
134	Alzheimer's β -Amyloid Protein Is Covalently Modified when Dissolved in Formic Acid. Journal of Neurochemistry, 1990, 54, 2050-2056.	3.9	26
135	Investigating Gains in Neurocognition in an Intervention Trial of Exercise (IGNITE): Protocol. Contemporary Clinical Trials, 2019, 85, 105832.	1.8	26
136	Comparison of CSF biomarkers in Down syndrome and autosomal dominant Alzheimer's disease: a cross-sectional study. Lancet Neurology, The, 2021, 20, 615-626.	10.2	26
137	Aggregation of β^2 Amyloid Peptide Is Promoted by Membrane Phospholipid Metabolites Elevated in Alzheimer's Disease Brain. Journal of Neurochemistry, 1997, 69, 266-272.	3.9	25
138	Association of sleep with cognition and beta amyloid accumulation in adults with Down syndrome. Neurobiology of Aging, 2020, 93, 44-51.	3.1	24
139	Role of biomarkers in studies of presymptomatic Alzheimer's disease. , 2005, 1, 145-151.		23
140	Measuring Target Effect of Proposed Disease-Modifying Therapies in Alzheimer's Disease. Neurotherapeutics, 2008, 5, 381-390.	4.4	23
141	Alzheimer-Like Pattern of Hypometabolism Emerges with Elevated Amyloid- β^2 Burden in Down Syndrome. Journal of Alzheimer's Disease, 2017, 61, 631-644.	2.6	23
142	Synthesis and ¹¹ C-labelling of (E,E)-1-(3,4-dihydroxystyryl)-4-(3-methoxy-4-hydroxystyryl) benzene for PET imaging of amyloid deposits?. Journal of Labelled Compounds and Radiopharmaceuticals, 2002, 45, 647-664.	1.0	22
143	The use of Centiloids for applying [¹¹ C]PiB classification cutoffs across region-of-interest delineation methods. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2018, 10, 332-339.	2.4	22
144	Peripheral inflammatory biomarkers predict the deposition and progression of amyloid- β^2 in cognitively unimpaired older adults. Brain, Behavior, and Immunity, 2021, 95, 178-189.	4.1	22

#	ARTICLE	IF	CITATIONS
145	Development and Screening of Contrast Agents for In Vivo Imaging of Parkinson's Disease. <i>Molecular Imaging and Biology</i> , 2013, 15, 585-595.	2.6	21
146	Imaging neurodegeneration in Down syndrome: brain templates for amyloid burden and tissue segmentation. <i>Brain Imaging and Behavior</i> , 2019, 13, 345-353.	2.1	21
147	What Is T+? A Gordian Knot of Tracers, Thresholds, and Topographies. <i>Journal of Nuclear Medicine</i> , 2021, 62, 614-619.	5.0	21
148	Apolipoprotein E and Alpha-1-Antichymotrypsin Genotypes Do Not Predict Time to Psychosis in Alzheimer's Disease. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2002, 15, 24-30.	2.3	20
149	Cognitive indicators of transition to preclinical and prodromal stages of Alzheimer's disease in Down syndrome. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020, 12, e12096.	2.4	20
150	Amyloid accumulation in Down syndrome measured with amyloid load. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020, 12, e12020.	2.4	19
151	A randomized controlled trial of amyloid positron emission tomography results disclosure in mild cognitive impairment. <i>Alzheimer's and Dementia</i> , 2020, 16, 1330-1337.	0.8	19
152	Associations between NIH Toolbox Cognition Battery and <i>in vivo</i> brain amyloid and tau pathology in non-demented older adults. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020, 12, e12018.	2.4	17
153	Physical activity and cognitive and imaging biomarkers of Alzheimer's disease in down syndrome. <i>Neurobiology of Aging</i> , 2021, 107, 118-127.	3.1	17
154	Detection of Brain Tau Pathology in Down Syndrome Using Plasma Biomarkers. <i>JAMA Neurology</i> , 2022, 79, 797.	9.0	17
155	NMR Identification of the Formic Acid-Modified Residue in Alzheimer's Amyloid Protein. <i>Journal of Neurochemistry</i> , 1994, 62, 349-354.	3.9	15
156	Cerebrospinal fluid biomarkers of Alzheimer's disease in a cohort of adults with Down syndrome. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020, 12, e12057.	2.4	15
157	Hippocampal sclerosis, TDP43, and the duration of the symptoms of dementia of AD patients. <i>Annals of Clinical and Translational Neurology</i> , 2020, 7, 1546-1556.	3.7	15
158	Influence of apolipoprotein-E genotype on brain amyloid load and longitudinal trajectories. <i>Neurobiology of Aging</i> , 2020, 94, 111-120.	3.1	15
159	PET measurement of longitudinal amyloid load identifies the earliest stages of amyloid-beta accumulation during Alzheimer's disease progression in Down syndrome. <i>NeuroImage</i> , 2021, 228, 117728.	4.2	15
160	Comparing amyloid- β plaque burden with antemortem PiB PET in autosomal dominant and late-onset Alzheimer disease. <i>Acta Neuropathologica</i> , 2021, 142, 689-706.	7.7	15
161	Leisure Activity, Brain Amyloid, and Episodic Memory in Adults with Down Syndrome. <i>Developmental Neurobiology</i> , 2019, 79, 738-749.	3.0	14
162	The effect of amyloid deposition on longitudinal resting-state functional connectivity in cognitively normal older adults. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 7.	6.2	14

#	ARTICLE	IF	CITATIONS
163	Predicting resistance to amyloid-beta deposition and cognitive resilience in the oldest-old. <i>Neurology</i> , 2020, 95, e984-e994.	1.1	14
164	Imaging Tau Deposits In Vivo: Progress in Viewing More of The Proteopathy Picture. <i>Neuron</i> , 2013, 79, 1035-1037.	8.1	13
165	Impact of partial volume correction on the regional correspondence between in vivo [C-11]PiB PET and postmortem measures of A β load. <i>NeuroImage: Clinical</i> , 2018, 19, 182-189.	2.7	13
166	Longitudinal trajectories of amyloid deposition, cortical thickness, and tau in Down syndrome: A deep phenotyping case report. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2019, 11, 654-658.	2.4	13
167	Comparison of longitudinal A β in nondemented elderly and Down syndrome. <i>Neurobiology of Aging</i> , 2019, 73, 171-176.	3.1	13
168	Cerebral Amyloid Deposition and Dual-Tasking in Cognitively Normal, Mobility Unimpaired Older Adults. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2016, 72, glw211.	3.6	12
169	Metabolic correlates of prevalent mild cognitive impairment and Alzheimer's disease in adults with Down syndrome. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020, 12, e12028.	2.4	12
170	Biopsy Support for the Validity of Pittsburgh Compound B Positron Emission Tomography With a Twist. <i>Archives of Neurology</i> , 2008, 65, 1281-3.	4.5	11
171	Molecular imaging: What is right and what is an illusion?. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2018, 10, 217-220.	2.4	11
172	A survey of attitudes toward clinical trials and genetic disclosure in autosomal dominant Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2015, 7, 50.	6.2	10
173	Synergism of antihypertensives and cholinesterase inhibitors in Alzheimer's disease. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2018, 4, 542-555.	3.7	10
174	Relationship of amyloid- β 42 in blood and brain amyloid: Ginkgo Evaluation of Memory Study. <i>Brain Communications</i> , 2020, 2, fcz038.	3.3	10
175	Structural determinants of activity at the GABAB receptor. <i>Molecular and Chemical Neuropathology</i> , 1995, 26, 15-30.	1.0	9
176	Blood and CSF biomarkers for AD revisited: what's new, what's good, and is this where we should be looking?. <i>Neurobiology of Aging</i> , 2002, 23, 517-519.	3.1	9
177	Whatever Happened to Pittsburgh Compound-A?. <i>Alzheimer Disease and Associated Disorders</i> , 2008, 22, 198-203.	1.3	9
178	Endogenous murine A β increases amyloid deposition in APP23 but not in APPPS1 transgenic mice. <i>Neurobiology of Aging</i> , 2015, 36, 2241-2247.	3.1	9
179	Neurofibrillary tau depositions emerge with subthreshold cerebral beta-amyloidosis in down syndrome. <i>NeuroImage: Clinical</i> , 2021, 31, 102740.	2.7	9
180	Amyloid Imaging with PET in Alzheimer's Disease, Mild Cognitive Impairment, and Clinically Unimpaired Subjects. , 2009, , 119-147.		9

#	ARTICLE	IF	CITATIONS
181	Where is hippocampal activity in the cascade of Alzheimer's disease biomarkers?. <i>Brain</i> , 2015, 138, 831-833.	7.6	8
182	Association Between Amyloid- β , Small-vessel Disease, and Neurodegeneration Biomarker Positivity, and Progression to Mild Cognitive Impairment in Cognitively Normal Individuals. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2019, 74, 1753-1760.	3.6	8
183	11C-PiB PET can underestimate brain amyloid- β burden when cotton wool plaques are numerous. <i>Brain</i> , 2022, 145, 2161-2176.	7.6	8
184	Research Use of Ecological Momentary Assessment for Adverse Event Monitoring Following Amyloid- β Results Disclosure. <i>Journal of Alzheimer's Disease</i> , 2019, 71, 1071-1079.	2.6	7
185	Alzheimer's disease pathology in a community-based sample of older adults without dementia: The MYHAT neuroimaging study. <i>Brain Imaging and Behavior</i> , 2021, 15, 1355-1363.	2.1	7
186	Patterns of glucose hypometabolism in Down syndrome resemble sporadic Alzheimer's disease except for the putamen. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020, 12, e12138.	2.4	7
187	Amyloid and neurodegeneration. <i>Neurology</i> , 2013, 81, 1728-1729.	1.1	6
188	Amyloid deposition is associated with different patterns of hippocampal connectivity in men versus women. <i>Neurobiology of Aging</i> , 2019, 76, 141-150.	3.1	6
189	Development of a PET radioligand selective for cerebral amyloid angiopathy. <i>Nuclear Medicine and Biology</i> , 2021, 92, 85-96.	0.6	6
190	Effect of phosphomonoesters, phosphodiesterases, and phosphocreatine on glutamate uptake by synaptic vesicles. <i>Molecular and Chemical Neuropathology</i> , 1997, 32, 89-99.	1.0	5
191	Robust White Matter Hyperintensity Segmentation On Unseen Domain. , 2021, 2021, 1047-1051.		5
192	An Effect of Education on Memory-Encoding Activation in Subjective Cognitive Decline. <i>Journal of Alzheimer's Disease</i> , 2021, 81, 1065-1078.	2.6	5
193	The roles of study setting, response bias, and personality in subjective memory complaints of cognitively normal older adults. <i>International Psychogeriatrics</i> , 2020, 33, 1-12.	1.0	3
194	Multi-Domain Learning By Meta-Learning: Taking Optimal Steps In Multi-Domain Loss Landscapes By Inner-Loop Learning. , 2021, 2021, 650-654.		3
195	Simplified quantification of PIB amyloid imaging PET studies. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2005, 25, S589-S589.	4.3	3
196	Quantitative PET and Histology of Brain Biopsy Reveal Lack of Selective Pittsburgh Compound-B Binding to Intracerebral Amyloidoma. <i>Journal of Alzheimer's Disease</i> , 2018, 65, 71-77.	2.6	2
197	14 Amyloid Imaging and (What is "Normal"?) Aging. , 2009, , 191-244.		2
198	Cortical atrophy and amyloid and tau deposition in Down syndrome: A longitudinal study. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2022, 14, e12288.	2.4	2

#	ARTICLE	IF	CITATIONS
199	Support vector machine learning and diffusion-derived structural networks predict amyloid quantity and cognition in adults with Down's syndrome. <i>Neurobiology of Aging</i> , 2022, 115, 112-121.	3.1	2
200	Biomarker clustering in autosomal dominant Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2023, 19, 274-284.	0.8	2
201	Magnetic Resonance Spectroscopy of Neural Tissue. <i>Methods in Neurosciences</i> , 1996, , 178-208.	0.5	1
202	Anomalous PiB enhancement in the Superior Sagittal and Transverse Venous Sinuses. <i>Alzheimer Disease and Associated Disorders</i> , 2012, 26, 186-190.	1.3	1
203	Positron emission tomography imaging of amyloid-beta plaque deposition: a decade of translation. <i>Journal of Translational Medicine</i> , 2012, 10, .	4.4	1
204	ICâ€06â€04: SLEEP, COGNITION, AND Î²â€AMYLOID IN ADULTS WITH DOWN SYNDROME. <i>Alzheimer's and Dementia</i> , 2019, 15, P12.	0.8	1
205	White matter microstructure and episodic memory in adults with down syndrome: A Tractâ€Based Spatial Statistics (TBSS) Study. <i>Alzheimer's and Dementia</i> , 2020, 16, e044673.	0.8	1
206	The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. , 2011, 7, 263.		1
207	Statistical Methods for Processing Neuroimaging Data from Two Different Sites with a Down Syndrome Population Application. <i>Communications in Computer and Information Science</i> , 2020, , 367-379.	0.5	1
208	White matter microstructure associations to amyloid burden in adults with Down syndrome. <i>NeuroImage: Clinical</i> , 2022, 33, 102908.	2.7	1
209	Brain health correlates of mobility-related confidence. <i>Experimental Gerontology</i> , 2022, 163, 111776.	2.8	1
210	Jointâ€label fusion brain atlases for dementia research in Down syndrome. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2022, 14, .	2.4	1
211	Commentary on â€Diagnosis of Alzheimer's disease: Two decades of progress.â€ <i>Diagnosis of Alzheimer's disease: Walking a well-paved path.</i> , 2005, 1, 99-100.		0
212	P3â€440: COMPARING THE CENTILOID SCALE FOR PITTSBURGH COMPOUND B AND FLORBETAPIR IN LONGITUDINAL PET STUDIES OF SPORADIC AD. <i>Alzheimer's and Dementia</i> , 2018, 14, P1283.	0.8	0
213	O2â€03â€06: PREDICTING RESILIENCY AGAINST AMYLOIDâ€BETA DEPOSITION, COGNITIVE IMPAIRMENT, AND THEIR COMBINATION IN THE OLDESTâ€OLD. <i>Alzheimer's and Dementia</i> , 2018, 14, P619.	0.8	0
214	ICâ€Pâ€10: COMPARISON OF IN VIVO [Fâ€18]AVâ€1451 OFFâ€TARGET RETENTION IN AFRICANâ€AMERICANS AND CAUCASIANS. <i>Alzheimer's and Dementia</i> , 2018, 14, P173.	0.8	0
215	P1â€421: COMPARISON OF STRIATAL LONGITUDINAL CHANGES IN AMYLOID DEPOSITION IN NONâ€DEMENTED ELDERLY AND DOWN SYNDROME. <i>Alzheimer's and Dementia</i> , 2018, 14, P467.	0.8	0
216	ICâ€Pâ€009: COMPARING THE CENTILOID SCALE FOR PITTSBURGH COMPOUND B AND FLORBETAPIR IN LONGITUDINAL PET STUDIES OF SPORADIC AD. <i>Alzheimer's and Dementia</i> , 2018, 14, P19.	0.8	0

#	ARTICLE	IF	CITATIONS
217	ICâ€Pâ€020: PREDICTING RESILIENCY AGAINST AMYLOIDâ€BETA DEPOSITION, COGNITIVE IMPAIRMENT, AND THEIR COMBINATION IN THE OLDESTâ€OLD. Alzheimer's and Dementia, 2018, 14, P25.	0.8	0
218	ICâ€Pâ€004: AMYLOID BURDEN AND CORTICAL ATROPHY IN NONâ€DEMENTED DOWN SYNDROME. Alzheimer's and Dementia, 2018, 14, P16.	0.8	0
219	P1â€437: PULSE WAVE VELOCITY IS ASSOCIATED WITH INCIDENT DEMENTIA AND AMYLOID DEPOSITION IN THE BRAINS OF ELDERLY ADULTS. Alzheimer's and Dementia, 2018, 14, P477.	0.8	0
220	P1â€429: COMPARISON OF IN VIVO [Fâ€18]AVâ€1451 OFFâ€TARGET RETENTION IN AFRICAN AMERICANS AND CAUCASIANS. Alzheimer's and Dementia, 2018, 14, P473.	0.8	0
221	P1â€445: AMYLOID BURDEN AND CORTICAL ATROPHY IN NONâ€DEMENTED DOWN SYNDROME. Alzheimer's and Dementia, 2018, 14, P484.	0.8	0
222	FTS3â€01â€01: HISTORY OF AMYLOID PET. Alzheimer's and Dementia, 2018, 14, P1004.	0.8	0
223	P4â€631: ALZHEIMER'S DISEASE PATHOLOGY IN A COMMUNITYâ€BASED SAMPLE OF OLDER ADULTS WITHOUT DEMENTIA: A POPULATIONâ€NEUROSCIENCE APPROACH. Alzheimer's and Dementia, 2019, 15, P1569.	0.8	0
224	ICâ€06â€03: SPATIAL ASSOCIATIONS OF AÎ² WITH TAU DEPOSITION IN DOWN SYNDROME. Alzheimer's and Dementia, 2019, 15, P11.	0.8	0
225	ICâ€06â€02: ASSOCIATIONS BETWEEN AÎ² AND TAU IN ADULTS WITH DOWN SYNDROME. Alzheimer's and Dementia, 2019, 15, P11.	0.8	0
226	ICâ€06â€01: ASSESSMENT OF LONGITUDINAL AMYLOID LOAD CHANGE IN DOWN SYNDROME. Alzheimer's and Dementia, 2019, 15, P10.	0.8	0
227	Evaluation of amyloid and tau PET quantitation methods using a 3Dâ€printed anatomically accurate brain phantom. Alzheimer's and Dementia, 2020, 16, e045455.	0.8	0
228	Characterization of point-spread function specification error on Geometric Transfer Matrix partial volume correction in [11C]PiB amyloid imaging. EJNMMI Physics, 2021, 8, 54.	2.7	0
229	Comparing Pathological Risk Factors for Dementia between Cognitively Normal Japanese and Americans. Brain Sciences, 2021, 11, 1180.	2.3	0
230	CSF Biomarkers in Down Syndrome and Autosomal Dominant Alzheimer Disease. SSRN Electronic Journal, 0, , .	0.4	0